BEGIN:VCALENDAR
VERSION:2.0
PRODID:-//Pharmaconomics//FDA Catalyst Calendar//EN
CALSCALE:GREGORIAN
METHOD:PUBLISH
BEGIN:VEVENT
UID:pharmaconomics-32@pharmaconomics
DTSTAMP:20260707T021608Z
DTSTART;VALUE=DATE:20270219
DTEND;VALUE=DATE:20270220
SUMMARY:RHHBY Phase 3 — Giredestrant
DESCRIPTION:Phase 3 trial results for Giredestrant in Estrogen Receptor-Positive\, HER2-Negative Advanced Breast Cancer are due Feb 19\, 2027. A clean hit validates the program\; a miss can gap the stock down hard.\n\nPrimary source: https://clinicaltrials.gov/study/NCT06065748\n\nTrack it: https://pharmaconomics.com/e/32
URL:https://pharmaconomics.com/e/32
TRANSP:TRANSPARENT
BEGIN:VALARM
TRIGGER:-P1D
ACTION:DISPLAY
DESCRIPTION:RHHBY catalyst tomorrow
END:VALARM
END:VEVENT
END:VCALENDAR